Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
267,515,765
-
Total 13F shares
-
5,838,884
-
Share change
-
-1,144,678
-
Total reported value
-
$58,387,367
-
Put/Call ratio
-
40%
-
Price per share
-
$10.00
-
Number of holders
-
13
-
Value change
-
+$5,986,757
-
Number of buys
-
5
-
Number of sells
-
21
Institutional Holders of Sana Biotechnology, Inc. - Common Stock (SANA) as of Q1 2024
As of 31 Mar 2024,
Sana Biotechnology, Inc. - Common Stock (SANA) was held by
13 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,838,884 shares.
The largest 10 holders included
CITADEL ADVISORS LLC, MORGAN STANLEY, JPMORGAN CHASE & CO, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, DEUTSCHE BANK AG\, Bank of New York Mellon Corp, NORGES BANK, Legal & General Group Plc, Erste Asset Management GmbH, and Voya Investment Management LLC.
This page lists
16
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.